Workflow
BioNTech SE(BNTX)
icon
Search documents
BioNTech SE(BNTX) - 2021 Q4 - Annual Report
2022-03-29 16:00
Exhibit 99.1 BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 1 1 • Fourth quarter and full year revenues of €5.5 billion and €19.0 billion , respectively 2 • Full year net income of €10.3 billion and fully diluted earnings per share of €39.63 ($46.87 ) • Expect to authorize a share repurchase program of up to $1.5 billion over the next two years and will propose a special cash dividend of €2.00 per share, pending approval at the Annual General Meeting • Approximat ...
BioNTech SE (BNTX) CEO Ugur Sahin on JPMorgan 40th Annual Healthcare Conference (Transcript)
2022-01-11 20:34
BioNTech SE (NASDAQ:BNTX) JPMorgan 40th Annual Healthcare Conference Call January 11, 2022 9:45 AM ET Company Participants Ugur Sahin - Co-Founder & Chief Executive Officer Jens Holstein - Chief Financial Officer Sean Marett - Chief Business & Commercial Officer Ozlem Tureci - Chief Medical Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Cory Kasimov - JPMorgan Chase & Co. Cory Kasimov Great. Good morning or good afternoon from the 40th Annual JPMorgan Healthcare Conference. My ...
BioNTech SE(BNTX) - 2020 Q4 - Annual Report
2021-03-29 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...
BioNTech SE(BNTX) - 2019 Q4 - Annual Report
2020-03-31 20:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...